FDG-PET/CT in the Postoperative Period: Utility, Expected Findings, Complications, and Pitfalls
FDG-PET/CT as a modality is increasingly used for detection of recurrence and for restaging in patients with clinical suspicion of malignancy, as well as in patients with elevated tumor markers. However, there are many pitfalls in the interpretation of these scans when the studies are performed afte...
Gespeichert in:
Veröffentlicht in: | Seminars in nuclear medicine 2017-11, Vol.47 (6), p.579-594 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 594 |
---|---|
container_issue | 6 |
container_start_page | 579 |
container_title | Seminars in nuclear medicine |
container_volume | 47 |
creator | Garg, Gunjan Benchekroun, Mohammed Taoudi Abraham, Tony |
description | FDG-PET/CT as a modality is increasingly used for detection of recurrence and for restaging in patients with clinical suspicion of malignancy, as well as in patients with elevated tumor markers. However, there are many pitfalls in the interpretation of these scans when the studies are performed after some treatment. Some of these are attributed to normal physiological distribution and are compounded when there are inflammatory changes occurring after surgery. The body's inherent response to the surgical insult results in this inflammation. In addition, there are also complications that can happen following surgery, causing increased FDG uptake. Despite various fallacies, FDG-PET/CT provides valuable information in evaluation of residual and recurrent malignant disease. In this article, we aim to describe some of these postsurgical changes secondary to inflammation, common surgical complications, and finally, the utility of FDG-PET/CT in these patients to detect recurrent disease, even in the background of postsurgical changes. |
doi_str_mv | 10.1053/j.semnuclmed.2017.07.005 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1946428581</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0001299817300582</els_id><sourcerecordid>1946428581</sourcerecordid><originalsourceid>FETCH-LOGICAL-c440t-7639a6c4474168f1bffab03911a4bd595c3285353bca0fde6498acae82a7b6003</originalsourceid><addsrcrecordid>eNqFkE1v2zAMhoViQ5tl-wuFjjvUKWVbtrTbliXdgALLIT0LskR3CmzLk5Si_fdTkBY7DiBAEnz59RBCGawY8Or2sIo4TkczjGhXJbB2BdmAX5AF41wUdVNW78gCAFhRSimuyIcYDwAl55JfkqtSyEa2XCyI2n6_K3ab_e16T91E02-kOx-TnzHo5J5yhsF5-4U-JDe49HJDN88zmoSWbt1k3fQYb-jaj_PgTG7wU071ZOnOpV4PQ_xI3mcf8dOrX5KH7Wa__lHc_7r7uf56X5i6hlS0TSV1k-O2Zo3oWdf3uoNKMqbrzuajTVUKXvGqMxp6i00thTYaRanbrgGoluTzee4c_J8jxqRGFw0Og57QH6Nism7qPEKwLBVnqQk-xoC9moMbdXhRDNQJrzqof3jVCa-CbLmyJNevW47dqfbW-MYzC76dBZh_fXIYVDQOJ4PWhUxNWe_-v-Uv_iiQSw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1946428581</pqid></control><display><type>article</type><title>FDG-PET/CT in the Postoperative Period: Utility, Expected Findings, Complications, and Pitfalls</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Garg, Gunjan ; Benchekroun, Mohammed Taoudi ; Abraham, Tony</creator><creatorcontrib>Garg, Gunjan ; Benchekroun, Mohammed Taoudi ; Abraham, Tony</creatorcontrib><description>FDG-PET/CT as a modality is increasingly used for detection of recurrence and for restaging in patients with clinical suspicion of malignancy, as well as in patients with elevated tumor markers. However, there are many pitfalls in the interpretation of these scans when the studies are performed after some treatment. Some of these are attributed to normal physiological distribution and are compounded when there are inflammatory changes occurring after surgery. The body's inherent response to the surgical insult results in this inflammation. In addition, there are also complications that can happen following surgery, causing increased FDG uptake. Despite various fallacies, FDG-PET/CT provides valuable information in evaluation of residual and recurrent malignant disease. In this article, we aim to describe some of these postsurgical changes secondary to inflammation, common surgical complications, and finally, the utility of FDG-PET/CT in these patients to detect recurrent disease, even in the background of postsurgical changes.</description><identifier>ISSN: 0001-2998</identifier><identifier>EISSN: 1558-4623</identifier><identifier>DOI: 10.1053/j.semnuclmed.2017.07.005</identifier><identifier>PMID: 28969758</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Fluorodeoxyglucose F18 ; Humans ; Neoplasm Recurrence, Local ; Neoplasms - diagnostic imaging ; Positron Emission Tomography Computed Tomography ; Positron-Emission Tomography ; Postoperative Period ; Radiopharmaceuticals ; Retrospective Studies ; Tomography, X-Ray Computed</subject><ispartof>Seminars in nuclear medicine, 2017-11, Vol.47 (6), p.579-594</ispartof><rights>2017 Elsevier Inc.</rights><rights>Copyright © 2017 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c440t-7639a6c4474168f1bffab03911a4bd595c3285353bca0fde6498acae82a7b6003</citedby><cites>FETCH-LOGICAL-c440t-7639a6c4474168f1bffab03911a4bd595c3285353bca0fde6498acae82a7b6003</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1053/j.semnuclmed.2017.07.005$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28969758$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Garg, Gunjan</creatorcontrib><creatorcontrib>Benchekroun, Mohammed Taoudi</creatorcontrib><creatorcontrib>Abraham, Tony</creatorcontrib><title>FDG-PET/CT in the Postoperative Period: Utility, Expected Findings, Complications, and Pitfalls</title><title>Seminars in nuclear medicine</title><addtitle>Semin Nucl Med</addtitle><description>FDG-PET/CT as a modality is increasingly used for detection of recurrence and for restaging in patients with clinical suspicion of malignancy, as well as in patients with elevated tumor markers. However, there are many pitfalls in the interpretation of these scans when the studies are performed after some treatment. Some of these are attributed to normal physiological distribution and are compounded when there are inflammatory changes occurring after surgery. The body's inherent response to the surgical insult results in this inflammation. In addition, there are also complications that can happen following surgery, causing increased FDG uptake. Despite various fallacies, FDG-PET/CT provides valuable information in evaluation of residual and recurrent malignant disease. In this article, we aim to describe some of these postsurgical changes secondary to inflammation, common surgical complications, and finally, the utility of FDG-PET/CT in these patients to detect recurrent disease, even in the background of postsurgical changes.</description><subject>Fluorodeoxyglucose F18</subject><subject>Humans</subject><subject>Neoplasm Recurrence, Local</subject><subject>Neoplasms - diagnostic imaging</subject><subject>Positron Emission Tomography Computed Tomography</subject><subject>Positron-Emission Tomography</subject><subject>Postoperative Period</subject><subject>Radiopharmaceuticals</subject><subject>Retrospective Studies</subject><subject>Tomography, X-Ray Computed</subject><issn>0001-2998</issn><issn>1558-4623</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1v2zAMhoViQ5tl-wuFjjvUKWVbtrTbliXdgALLIT0LskR3CmzLk5Si_fdTkBY7DiBAEnz59RBCGawY8Or2sIo4TkczjGhXJbB2BdmAX5AF41wUdVNW78gCAFhRSimuyIcYDwAl55JfkqtSyEa2XCyI2n6_K3ab_e16T91E02-kOx-TnzHo5J5yhsF5-4U-JDe49HJDN88zmoSWbt1k3fQYb-jaj_PgTG7wU071ZOnOpV4PQ_xI3mcf8dOrX5KH7Wa__lHc_7r7uf56X5i6hlS0TSV1k-O2Zo3oWdf3uoNKMqbrzuajTVUKXvGqMxp6i00thTYaRanbrgGoluTzee4c_J8jxqRGFw0Og57QH6Nism7qPEKwLBVnqQk-xoC9moMbdXhRDNQJrzqof3jVCa-CbLmyJNevW47dqfbW-MYzC76dBZh_fXIYVDQOJ4PWhUxNWe_-v-Uv_iiQSw</recordid><startdate>201711</startdate><enddate>201711</enddate><creator>Garg, Gunjan</creator><creator>Benchekroun, Mohammed Taoudi</creator><creator>Abraham, Tony</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201711</creationdate><title>FDG-PET/CT in the Postoperative Period: Utility, Expected Findings, Complications, and Pitfalls</title><author>Garg, Gunjan ; Benchekroun, Mohammed Taoudi ; Abraham, Tony</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c440t-7639a6c4474168f1bffab03911a4bd595c3285353bca0fde6498acae82a7b6003</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Fluorodeoxyglucose F18</topic><topic>Humans</topic><topic>Neoplasm Recurrence, Local</topic><topic>Neoplasms - diagnostic imaging</topic><topic>Positron Emission Tomography Computed Tomography</topic><topic>Positron-Emission Tomography</topic><topic>Postoperative Period</topic><topic>Radiopharmaceuticals</topic><topic>Retrospective Studies</topic><topic>Tomography, X-Ray Computed</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Garg, Gunjan</creatorcontrib><creatorcontrib>Benchekroun, Mohammed Taoudi</creatorcontrib><creatorcontrib>Abraham, Tony</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Seminars in nuclear medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Garg, Gunjan</au><au>Benchekroun, Mohammed Taoudi</au><au>Abraham, Tony</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>FDG-PET/CT in the Postoperative Period: Utility, Expected Findings, Complications, and Pitfalls</atitle><jtitle>Seminars in nuclear medicine</jtitle><addtitle>Semin Nucl Med</addtitle><date>2017-11</date><risdate>2017</risdate><volume>47</volume><issue>6</issue><spage>579</spage><epage>594</epage><pages>579-594</pages><issn>0001-2998</issn><eissn>1558-4623</eissn><abstract>FDG-PET/CT as a modality is increasingly used for detection of recurrence and for restaging in patients with clinical suspicion of malignancy, as well as in patients with elevated tumor markers. However, there are many pitfalls in the interpretation of these scans when the studies are performed after some treatment. Some of these are attributed to normal physiological distribution and are compounded when there are inflammatory changes occurring after surgery. The body's inherent response to the surgical insult results in this inflammation. In addition, there are also complications that can happen following surgery, causing increased FDG uptake. Despite various fallacies, FDG-PET/CT provides valuable information in evaluation of residual and recurrent malignant disease. In this article, we aim to describe some of these postsurgical changes secondary to inflammation, common surgical complications, and finally, the utility of FDG-PET/CT in these patients to detect recurrent disease, even in the background of postsurgical changes.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28969758</pmid><doi>10.1053/j.semnuclmed.2017.07.005</doi><tpages>16</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0001-2998 |
ispartof | Seminars in nuclear medicine, 2017-11, Vol.47 (6), p.579-594 |
issn | 0001-2998 1558-4623 |
language | eng |
recordid | cdi_proquest_miscellaneous_1946428581 |
source | MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | Fluorodeoxyglucose F18 Humans Neoplasm Recurrence, Local Neoplasms - diagnostic imaging Positron Emission Tomography Computed Tomography Positron-Emission Tomography Postoperative Period Radiopharmaceuticals Retrospective Studies Tomography, X-Ray Computed |
title | FDG-PET/CT in the Postoperative Period: Utility, Expected Findings, Complications, and Pitfalls |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T06%3A24%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=FDG-PET/CT%20in%20the%20Postoperative%20Period:%20Utility,%20Expected%20Findings,%20Complications,%20and%20Pitfalls&rft.jtitle=Seminars%20in%20nuclear%20medicine&rft.au=Garg,%20Gunjan&rft.date=2017-11&rft.volume=47&rft.issue=6&rft.spage=579&rft.epage=594&rft.pages=579-594&rft.issn=0001-2998&rft.eissn=1558-4623&rft_id=info:doi/10.1053/j.semnuclmed.2017.07.005&rft_dat=%3Cproquest_cross%3E1946428581%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1946428581&rft_id=info:pmid/28969758&rft_els_id=S0001299817300582&rfr_iscdi=true |